Breath Actuated Inhaler

Aptar Pharma's SimpliSqueeze® is a leading packaging and dispensing solution for liquid pharmaceuticals. It improves patient compliance and is preferred over traditional packaging by consumers.

Aptar Pharma's VP3 technology platform has been the industry standard for multi-dose nasal sprays for 40+ years, serving as the go-to pump for anti-allergic treatments in originator brands, generics, and local/systemic therapies.

Aptar Pharma's VP7 platform was developed for nasal and sublingual drug administration, successfully delivering popular prescription drugs globally in Asia, Europe, and the USA.

Aptar Pharma's APF Futurity™, the first recyclable nasal spray pump, has been rated as "highly recyclable" by the cyclos-HTP institute in 2022. The spray leverages Aptar's Tip Seal technology suitable for preservative-free formulations, including nasal saline or similar OTC compounds. The design allow...

Aptar Digital Health is a global leader in end-to-end digital solutions that enhance patient experiences. We combine our unmatched expertise with a diverse, industry-leading portfolio of products and platforms. Our holistic ecosystem includes mobile and web applications, sensors and wearables, and connecte...

Aptar Pharma's Bidose (BDS) is a two-shot, user-friendly nasal delivery device for liquid drugs. This sturdy, self-priming system permits accurate, one-handed operation, enabling non-invasive, systemic drug delivery without the assistance of a healthcare professional.

Aptar Pharma offers nasal vaccine solutions, suitable for liquid and powder formulations, that ensure precise dosing and ease of use for healthcare professionals. These non-injectable alternatives potentially decrease cold chain storage needs, enhancing distribution.

Aptar Pharma's PremiumCoat(R) offers state-of-the-art ETFE-coated stoppers and plungers, combining superior container closure integrity and compatibility. With its highest standard specifications, it ensures optimal particulate protection for sensitive drugs.

Aptar Pharma's Unidose systems are nasal drug delivery devices for both liquid and powder forms, enabling precise single-dose delivery without healthcare professional intervention.

Aptar Pharma's CPS spray pump offers precise, reliable, and targeted preservative-free nasal drug delivery.

Aptar Pharma's Prohaler® is a patient-centric, high-performance DPI that ensures optimal patient compliance in treating asthma, COPD, and other pulmonary conditions.

Aptar Pharma’s DF30 metering valve platform is the industry standard for safe and precise medication delivery to patients with life-threatening pulmonary diseases. It is also the benchmark for hydrofluoralkane (HFA) propellant pMDIs. As the pharmaceutical industry shifts towards environmentally friendl...

Aptar Pharma's presentation entitled "Innovations in Inhalation" explores the current extensive portfolio of high-quality OINDP (Orally Inhaled and Nasal Drug Products) delivery devices. The presentation also highlights Aptar Pharma's comprehensive services which support respiratory drug development, including device selection, formulation development, analytical methods, and regulatory support. A key focus of the talk is the introduction of Orbital, an innovative high payload DPI system designed to enhance drug delivery efficiency and patient compliance. This discussion aims to showcase Aptar Pharma's latest advancements in inhalation technology, emphasizing their commitment to improving patient care through innovative drug delivery systems.

Big Pharma reports that up to over 90% of their CO2 emissions are scope 3. This is not only a huge burden but also the most difficult part to influence for pharmaceutical industry. However, there are ways to manage and collaborate in the industry. Christophe Marie from Aptar Group will highlight how Aptar implemented specific targets with partners and suppliers to tackle the scope 3 challenge, coming from a consumer market perspective, extrapolating into the pharmaceutical business. Also, when talking about products we are increasingly facing requests to minimize our CO2 footprint in Pharma. A great example for collaborative approaches helping to de-risk and accelerate our clients’ low GWP pressurized Metered Dose Inhaler (pMDI) programs will be illustrated by Chris Baron, based on the transition of the current pMDIs to alternative low GWP propellant technologies. Join Christophe Marie and Chris Baron at CPHI to learn how Aptar Pharma supports more sustainable product

Aptar Pharma Brochure